|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements of minimal residual disease (MRD) done by flow cytometry during treatment.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:AireweleGladstoneG,
pubmed-author:BowmanW PaulWP,
pubmed-author:CampanaDarioD,
pubmed-author:CaoXueyuanX,
pubmed-author:Coustan-SmithElaineE,
pubmed-author:DahlGaryG,
pubmed-author:DegarBarbaraB,
pubmed-author:DowningJames RJR,
pubmed-author:InabaHirotoH,
pubmed-author:LacayoNorman JNJ,
pubmed-author:LeungWingW,
pubmed-author:MeshinchiSoheilS,
pubmed-author:OnciuMihaelaM,
pubmed-author:PoundsStanleyS,
pubmed-author:PuiChing-HonCH,
pubmed-author:RaimondiSusana CSC,
pubmed-author:RazzoukBassem IBI,
pubmed-author:RibeiroRaul CRC,
pubmed-author:RubnitzJeffrey EJE,
pubmed-author:TaubJeffreyJ
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
543-52
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20451454-Adolescent,
pubmed-meshheading:20451454-Aminoglycosides,
pubmed-meshheading:20451454-Antibodies, Monoclonal,
pubmed-meshheading:20451454-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20451454-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20451454-Child,
pubmed-meshheading:20451454-Child, Preschool,
pubmed-meshheading:20451454-Cytarabine,
pubmed-meshheading:20451454-Cytogenetic Analysis,
pubmed-meshheading:20451454-Daunorubicin,
pubmed-meshheading:20451454-Disease-Free Survival,
pubmed-meshheading:20451454-Etoposide,
pubmed-meshheading:20451454-Female,
pubmed-meshheading:20451454-Flow Cytometry,
pubmed-meshheading:20451454-Humans,
pubmed-meshheading:20451454-Infant,
pubmed-meshheading:20451454-Infant, Newborn,
pubmed-meshheading:20451454-Leukemia, Myeloid, Acute,
pubmed-meshheading:20451454-Male,
pubmed-meshheading:20451454-Neoplasm, Residual,
pubmed-meshheading:20451454-Remission Induction,
pubmed-meshheading:20451454-Survival Rate,
pubmed-meshheading:20451454-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
|
|
pubmed:affiliation |
Department of Oncology, St Jude Children's Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105-2794, USA. jeffrey.rubnitz@stjude.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
